<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035397</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1597</org_study_id>
    <secondary_id>2012-004381-18</secondary_id>
    <nct_id>NCT02035397</nct_id>
  </id_info>
  <brief_title>Intragastric Injections of Botox for the Treatment of Obesity</brief_title>
  <official_title>Treatment of Morbid Obesity by Intragastric Injections of Botulinum Toxin A. A Randomized, Double-blind, Placebo Controlled, Phase II-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One possible angle for treating obesity could be slowing down the gastric emptying time. By&#xD;
      prolonging the gastric emptying time, the person would ideally experience increased sensation&#xD;
      of satiety, and in the long run reduce food intake. If such a treatment provides a clinically&#xD;
      significant weight loss, this could be an alternative for surgical procedures, avoiding the&#xD;
      risk for perioperative complications as well as complications in the long run.&#xD;
&#xD;
      There are now several pilot studies documenting that intragastric treatment with botulinum&#xD;
      toxin A (BTA) can be effective, although the treatment perspective is short and do not&#xD;
      include repeated injections. However, they demonstrate that BTA-injections are safe for the&#xD;
      patient. The treatment is administered by endoscopy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>Change from baseline to 6 months; 1 year; 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin type A injection in muscles of stomach wall</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline solution) injection first 6 months, then active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <arm_group_label>Botulinum toxin A</arm_group_label>
    <arm_group_label>Saline solution</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <arm_group_label>Saline solution</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 35&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to medication&#xD;
&#xD;
          -  Neuro muscular disease&#xD;
&#xD;
          -  Dysphagia&#xD;
&#xD;
          -  Tendency for aspiration&#xD;
&#xD;
          -  Ulcus&#xD;
&#xD;
          -  Use of aminoglycoside antibiotics and/or spectinomycin lately&#xD;
&#xD;
          -  Previous side effects of botox injections&#xD;
&#xD;
          -  Previous bariatric surgery&#xD;
&#xD;
          -  Previous cancer in GI-tract&#xD;
&#xD;
          -  Other obesity treatment last 12 months&#xD;
&#xD;
          -  Severe eating disorder&#xD;
&#xD;
          -  Hypothyroidism&#xD;
&#xD;
          -  Pregnancy/brest feeding&#xD;
&#xD;
          -  Reduced competence to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BÃ¥rd Kulseng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology, Fac MH, IKOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Olavs Hospital, Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 12, 2014</study_first_submitted>
  <study_first_submitted_qc>January 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>botulinum toxin</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Satiation</keyword>
  <keyword>Diet</keyword>
  <keyword>Weight Loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

